The compound LY2444296, which blocks the kappa opioid receptor, significantly reduces alcohol consumption in animal models of alcohol dependence. This study suggests LY2444296 could be a breakthrough in treating alcohol use disorder (AUD) by targeting the brain's KOP system, implicated in addiction and withdrawal symptoms.